New drug combo shows promise for tough cervical cancers
NCT ID NCT07266350
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will observe 1,300 patients with advanced or recurrent cervical cancer who are treated with camrelizumab, famitinib, or combinations of these drugs. The goal is to see how safe and effective these treatments are in real-world settings. Patients are placed into one of six groups based on their treatment plan, and data is collected over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab and famitinib
What this could lead to
If successful, this could provide real-world evidence that these drugs are safe and effective for treating advanced or recurrent cervical cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The drugs may cause side effects like immune-related reactions or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••